Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta granted priority review by FDA for traditional approval Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically meaningful improvement in estimat ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

Takeda Pharmaceutical Company (NYSE:TAK) Update / briefing March 28, 2026 08:30 PM ET Company ParticipantsChinwe Ukomadu - Head of Gastrointestinal and Inflammation Therapeutic Area UnitElizabeth Borgeson - Investor Relations OfficerHidemaru Yamaguchi - Managing DirectorHiroyuki Matsubara - Equity Research Senior AssociateJulie Kim - CEO-ElectRhonda Pacheco - President of U.S. Business UnitTony Ren - Head of Asia Healthcare ResearchConference Call ParticipantsSeiji Wakao - Executive Director and Senior Anal ...

Zasocitinib IR Event Phase 3 Psoriasis Data Presented at AAD March 28th, 2026 ET / March 29th, 2026 JST Photo: IFPA | All the Colors We Are This material is prepared and distributed solely for the purpose of providing information about Takeda's management or busine ss to shareholders, investors, and analysts, and is not intended to induce purchase or prescription of any specific drugs and other products. This material is not intended for healthcare professionals, patients, or other persons other than those ...

Merck & Co., Inc. (NYSE:MRK) is included in our list of the best stocks to buy for financial stability. Merck & Co. (NYSE) to Acquire Terns Pharma for $6.7 Billion On March 25, 2026, Merck & Co., Inc. (NYSE:MRK) came into the limelight when Reuters reported that the company had agreed to buy Terns Pharma for $6.7 billion. The move comes as the company looks to expand its cancer pipeline amid concerns surrounding the looming patent loss for blockbuster therapy Keytruda. By the end of this decade, Merck ...

Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient- reported outcomes compared to Taltz monotherapy in TOGETHER-PsA study Late-breaking results also published in Arthritis & Rheumatology INDIANAPOLIS, March 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in ...

Incyte's skin disease drug shows long-term symptom relief in late-stage trials | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Companies Incyte Corp Follow Abbvie Inc Follow Novartis AG Follow Show more companies Povorcitinib is a once-daily pill that works by blocking JAK1, a protein involved in the inflammation that leads to painful abscesses and nodules. Treatment options for the condition are limited and are mainly injectable drugs. There are curr ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care. ...

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed either Q4W or Q12W, showed progressively increasing efficacy, with no evidence of plateau at Week 24 across endpointsData reinforce potential for Q12W dosing from the start Paris, March 28, 2026. Positive results from three phase 3 studies of amlitelimab, a fully human non-T cell depleting monoclonal antibody t ...